Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127646601 | 12764660 | 1 | I | 2006 | 20160428 | 20160920 | 20160920 | PER | US-ASTRAZENECA-2016SE48130 | ASTRAZENECA | 61.00 | YR | M | Y | 81.60000 | KG | 20160921 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127646601 | 12764660 | 1 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | Y | 21153 | 40 | MG | CAPSULE | QD | |||||
| 127646601 | 12764660 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | Y | 21153 | 40 | MG | CAPSULE | QD | |||||
| 127646601 | 12764660 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | GENERIC 40 MG | U | Y | 21153 | CAPSULE | |||||||
| 127646601 | 12764660 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | GENERIC 40 MG | U | Y | 21153 | CAPSULE | |||||||
| 127646601 | 12764660 | 5 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | Y | 21153 | 40 | MG | CAPSULE | QD | |||||
| 127646601 | 12764660 | 6 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | Y | 21153 | 40 | MG | CAPSULE | QD | |||||
| 127646601 | 12764660 | 7 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | DAILY | 0 | CAPSULE | |||||||||
| 127646601 | 12764660 | 8 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 127646601 | 12764660 | 9 | C | DILTIAZEM. | DILTIAZEM | 1 | 0 | 180 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127646601 | 12764660 | 1 | Barrett's oesophagus |
| 127646601 | 12764660 | 2 | Helicobacter infection |
| 127646601 | 12764660 | 3 | Barrett's oesophagus |
| 127646601 | 12764660 | 4 | Helicobacter infection |
| 127646601 | 12764660 | 5 | Barrett's oesophagus |
| 127646601 | 12764660 | 6 | Helicobacter infection |
| 127646601 | 12764660 | 7 | Gastrooesophageal reflux disease |
| 127646601 | 12764660 | 8 | Blood cholesterol increased |
| 127646601 | 12764660 | 9 | Hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127646601 | 12764660 | Asthenia | |
| 127646601 | 12764660 | Chronic obstructive pulmonary disease | |
| 127646601 | 12764660 | Diarrhoea | |
| 127646601 | 12764660 | Drug ineffective | |
| 127646601 | 12764660 | Hypertension | |
| 127646601 | 12764660 | Intentional product misuse | |
| 127646601 | 12764660 | Intentional product use issue | |
| 127646601 | 12764660 | Nausea | |
| 127646601 | 12764660 | Off label use | |
| 127646601 | 12764660 | Peripheral swelling | |
| 127646601 | 12764660 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127646601 | 12764660 | 1 | 2006 | 0 | ||
| 127646601 | 12764660 | 2 | 2006 | 0 | ||
| 127646601 | 12764660 | 3 | 201604 | 0 | ||
| 127646601 | 12764660 | 4 | 201604 | 0 | ||
| 127646601 | 12764660 | 5 | 201604 | 0 | ||
| 127646601 | 12764660 | 6 | 201604 | 0 | ||
| 127646601 | 12764660 | 7 | 2004 | 2004 | 0 | |
| 127646601 | 12764660 | 8 | 2011 | 0 | ||
| 127646601 | 12764660 | 9 | 201511 | 0 |